Document is current

Article History

Received: 29 August 2023

Revised: 13 September 2023

Accepted: 20 September 2023

First Online: 4 October 2023

Competing interests

: NCPC, TE, KMP, AH and SS and received support from Novartis through the European Treatment and Outcome Study (EUTOS) for CML. NCPC has received research support and honoraria from Novartis, and honoraria from Incyte and Astellas. TE has received research support from BMS, Incyte, Novartis and Pfizer. SB is an advisory board member of Qiagen, Novartis, Terns and Cepheid, received honoraria from Qiagen, Novartis and Cepheid, and research funding from Novartis, Incyte and Cepheid. JMC has received honoraria from Novartis, Incyte, Qiagen and Cepheid. MD has served as a consultant for Ariad, Blueprint Medicine, Bristol Myers Squibb, CTI Biopharma, Cogent, Galena Biopharma, Incyte, Novartis, Pfizer and received research funding from Pfizer. DK served as a member of advisory board for Novartis and Paladin, and received honoraria and research grants from Novartis, Pfizer and Paladin. KMP has received honoraria from Angelini. JR has received honoraria from Novartis, Bristol, Myers Squibb, Takeda, Amgen, Cepheid and Genentech. AH has received institutional research support from Novartis, Bristol Myers Squibb, Incyte, and Pfizer and personal fees from Novartis and Incyte. JFA has received honoraria from Incyte and Novartis and research funding from Incyte and Pfizer. SS has received honoraria from Novartis and Incyte Biosciences. The remaining co-authors report no relevant disclosures.

: Data sharing not applicable to this article as no datasets were generated or analysed during the current study.